Loading
A phase 1/2 trial of Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by Multitude Therapeutics Inc., now recruiting.
AMT-116 in Combination With AK112 in Patients With Lung Cancer is a phase 1/2 interventional study registered as NCT07590531 by Multitude Therapeutics Inc., with 118 participants planned, started 2026-06-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: AMT-116, AK112. Conditions listed: Advanced Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AMT-116, Multitude Therapeutics.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Ivonescimab, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares AMT-116, Multitude Therapeutics.
Shares Ivonescimab, Bispecific antibodies, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/